Checked
Eli Lilly & Co
NYSE: LLY · Pharmaceutical Preparations · Indianapolis, IN
- Revenue
- $65.18B
- +44.7% vs. prior year
- Net income
- $20.64B
- 31.7% net margin
- Total assets
- $112.5B
- Diluted EPS
- $22.95
Company details
As reported to the SEC
- SEC CIK
- 59478
- Stock
- NYSE: LLY
- Legal Entity Identifier (LEI)
- FRDRIPF3EKNDJ2CQJL29
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- Lilly Corporate Ctr, Drop Code 1094, Indianapolis, IN 46285
- Incorporated in
- Indiana
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Phone
- (317) 276-2000
- Last annual report
- 02/12/2026
- Last quarterly report
- 08/05/2026
Formerly: LILLY ELI & CO (until 10/25/2019); LILLY ELI & CO ET AL (until 10/14/1994)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| Diluted earnings per share | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
| Research and development | $13.34B | $10.99B | $9.31B | $7.19B | $6.93B |
| Total assets | $112.5B | $78.72B | $64.01B | $49.49B | $48.81B |
| Shareholders' equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B |
| Cash and cash equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B |
| Long-term debt | $40.87B | $28.53B | $18.32B | $14.74B | $15.35B |
| Cash from operations | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B |
$24.54B
$28.32B
$28.54B
$34.12B
$45.04B
$65.18B
Federal and state records filed under the name Eli Lilly & Co
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
FDA recalls
Recalls of food, drugs and devices reported to the FDA
Swipe the table sideways to see more columns.
Drug shortages
Products this company makes or markets that are on the FDA drug shortage list
| Drug | Status |
|---|---|
| Insulin Glargine Injection | To Be Discontinued |
| Insulin Glargine-aglr Injection | To Be Discontinued |
| Insulin Lispro Injection | To Be Discontinued |
| Insulin Lispro Protamine and Insulin Lispro Injection | To Be Discontinued |
| Insulin Lispro-aabc Injection | To Be Discontinued |
| Lasmiditan Succinate Tablet | To Be Discontinued |
| Mirikizumab-mrkz Injection | To Be Discontinued |
Subsidiaries
157 companies that Eli Lilly & Co owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| ARMO Biosciences, Inc. | SEC 10-K |
| Adverum Biotechnologies, Inc. | SEC 10-K |
| Adverum NC, LLC | SEC 10-K |
| Akouos, Inc. | SEC 10-K |
| Alnara Pharmaceuticals, Inc. | SEC 10-K |
| Annapurna Therapeutics, Ltd. | SEC 10-K |
| Aparito Espanya S.L. | SEC 10-K |
| Aparito Limited | SEC 10-K |
| Avalanche Australia Pty Ltd. | SEC 10-K |
| Avid Radiopharmaceuticals, Inc. | SEC 10-K |
| CPD 4, Inc. | SEC 10-K |
| CoLucid Pharmaceuticals, Inc. | SEC 10-K |
| Compania Farmaceutica Eli Lilly de Centro America S.A. | SEC 10-K |
| DICE Alpha Inc. | SEC 10-K |
| DICE Molecules SV, Inc. | SEC 10-K |
| DICE Therapeutics, Inc. | SEC 10-K |
| Dermira, Inc. | SEC 10-K |
| Disarm Therapeutics Inc. | SEC 10-K |
| Dista Ilac Ticaret Limited Sirketi | SEC 10-K |
| Dista, S.A. | SEC 10-K |
| Dista-Produtos Quimicos & Farmaceuticos, LDA | SEC 10-K |
| ELC EHS, LLC | SEC 10-K |
| ELCO Dominicana S.R.L. | SEC 10-K |
| ELCO Insurance Company Limited | SEC 10-K |
| ELCO Management, Inc. | SEC 10-K |
| ELCO for Trading and Marketing, S.A.E. | SEC 10-K |
| ELGO Insurance Company Limited | SEC 10-K |
| ELI LILLY AND COMPANY (INDIA ) PRIVATE LIMITED | GLEIF |
| ELI LILLY GROUP PENSION TRUSTEES LIMITED | GLEIF |
| ELI LILLY KINSALE LIMITED | GLEIF, SEC 10-K |
| ELI LILLY SERVICES INDIA PRIVATE LIMITED | GLEIF, SEC 10-K |
| Eli Lilly (Malaysia) Sdn. Bhd. | SEC 10-K |
| Eli Lilly (Philippines), Incorporated | SEC 10-K |
| Eli Lilly (S.A.) (Proprietary) Limited | SEC 10-K |
| Eli Lilly (Singapore) Pte. Ltd. | SEC 10-K |
| Eli Lilly (Suisse) S.A. | SEC 10-K |
| Eli Lilly Asia Pacific SSC Sdn Bhd | SEC 10-K |
| Eli Lilly Asia, Inc. | SEC 10-K |
| Eli Lilly Australia Pty. Limited | SEC 10-K |
| Eli Lilly B-H d.o.o. | SEC 10-K |
| Eli Lilly Benelux S.A. | SEC 10-K |
| Eli Lilly Bienes y Servicios S. de R.L. de C.V. | SEC 10-K |
| Eli Lilly CR s.r.o. | SEC 10-K |
| Eli Lilly Canada Inc. | SEC 10-K |
| Eli Lilly Clinical Diagnostics Laboratory LLC | SEC 10-K |
| Eli Lilly Cork Limited | SEC 10-K |
| Eli Lilly Danmark A/S | SEC 10-K |
| Eli Lilly Drug Store LLC | SEC 10-K |
| Eli Lilly Egypt for Trading Company S.A.E. | SEC 10-K |
| Eli Lilly European Clinical Trial Services S.A. | SEC 10-K |
| Eli Lilly Export S.A. | SEC 10-K |
| Eli Lilly Finance, S.A. | SEC 10-K |
| Eli Lilly Ges.m.b.H. | SEC 10-K |
| Eli Lilly Group Limited | SEC 10-K |
| Eli Lilly Hrvatska d.o.o. | SEC 10-K |
| Eli Lilly Interamerica Inc., y Compania Limitada | SEC 10-K |
| Eli Lilly Interamerica, Inc. | SEC 10-K |
| Eli Lilly Ireland Holdings Limited | SEC 10-K |
| Eli Lilly Israel Ltd. | SEC 10-K |
| Eli Lilly Italia S.p.A. | SEC 10-K |
| Eli Lilly Japan K.K. | SEC 10-K |
| Eli Lilly Nederland B.V. | SEC 10-K |
| Eli Lilly Norge A.S. | SEC 10-K |
| Eli Lilly Pakistan (Pvt.) Ltd. | SEC 10-K |
| Eli Lilly Polska Sp. z.o.o. (Ltd.) | SEC 10-K |
| Eli Lilly Regional Operations GmbH | SEC 10-K |
| Eli Lilly Romania S.R.L. | SEC 10-K |
| Eli Lilly S.A. | SEC 10-K |
| Eli Lilly Saudi Arabia Limited | SEC 10-K |
| Eli Lilly Services Peru S.A.C | SEC 10-K |
| Eli Lilly Slovakia s.r.o. | SEC 10-K |
| Eli Lilly Sweden AB | SEC 10-K |
| Eli Lilly Vostok S.A. | SEC 10-K |
| Eli Lilly and Company (India) Pvt. Ltd. | SEC 10-K |
| Eli Lilly and Company (Ireland) Limited | SEC 10-K |
| Eli Lilly and Company (N.Z.) Limited | SEC 10-K |
| Eli Lilly and Company (Taiwan), Inc. | SEC 10-K |
| Eli Lilly de Costa Rica, S.R.L. | SEC 10-K |
| Eli Lilly do Brasil Limitada | SEC 10-K |
| Eli Lilly farmacevtska druzba, d.o.o. | SEC 10-K |
| Eli Lilly y Compania de Mexico, S.A. de C.V. | SEC 10-K |
| Eli Lilly y Compania de Venezuela, S.A. | SEC 10-K |
| Emergence Therapeutics France SAS | SEC 10-K |
| Glycostasis, Inc. | SEC 10-K |
| Greenfield-Produtos Farmaceuticos, Lda. | SEC 10-K |
| ICOS Corporation | SEC 10-K |
| ImClone LLC | SEC 10-K |
| ImClone Systems Holdings, Inc. | SEC 10-K |
| Irisfarma S.A. | SEC 10-K |
| Isopro Holdings LLC | SEC 10-K |
| KINSALE FINANCIAL SERVICES UNLIMITED COMPANY | GLEIF |
| LDH I Corporation | SEC 10-K |
| LDH II Corporation | SEC 10-K |
| LDH III Corporation | SEC 10-K |
| LDH IV Corporation | SEC 10-K |
| LDH V 2023 Corporation | SEC 10-K |
| LDH VI Corporation | SEC 10-K |
| LDH VII Corporation | SEC 10-K |
| LDH VIII Corporation | SEC 10-K |
| LILLY VENTURES FUND I LLC | GLEIF, SEC 10-K |
| Lilly (Beijing) Medical Tech Innovation Co., Ltd. | SEC 10-K |
| Lilly (Shanghai) Management Co., Ltd. | SEC 10-K |
| Lilly Asia Ventures Fund I, L.P. | SEC 10-K |
| Lilly Asia Ventures Fund II, L.P. | GLEIF, SEC 10-K |
| Lilly Asian Ventures Fund III, L.P. | SEC 10-K |
| Lilly Cayman Holdings | SEC 10-K |
| Lilly Centre for Clinical Pharmacology PTE. LTD. | SEC 10-K |
| Lilly China Research and Development Co., Ltd | SEC 10-K |
| Lilly Deutschland GmbH | SEC 10-K |
| Lilly France S.A.S. | SEC 10-K |
| Lilly Global Nederland Holdings B.V. | SEC 10-K |
| Lilly Global Services, Inc. | SEC 10-K |
| Lilly Holding GmbH | SEC 10-K |
| Lilly Holdings B.V. | SEC 10-K |
| Lilly Hungaria KFT | SEC 10-K |
| Lilly Ilac Ticaret Limited Sirketi | SEC 10-K |
| Lilly Japan Financing G.K. | SEC 10-K |
| Lilly Korea Ltd. | SEC 10-K |
| Lilly Lebanon Advanced Therapies LLC | SEC 10-K |
| Lilly Nederland Finance B.V. | GLEIF, SEC 10-K |
| Lilly Nederland Holding B.V. | SEC 10-K |
| Lilly Pharma Ltd. | SEC 10-K |
| Lilly Portugal - Produtos Farmaceuticos, Lda. | SEC 10-K |
| Lilly S.A. | SEC 10-K |
| Lilly Suzhou Pharmaceutical Co. Ltd. | SEC 10-K |
| Lilly Trading Co. LTD | SEC 10-K |
| Lilly USA, LLC | SEC 10-K |
| Lilly del Caribe, Inc. | SEC 10-K |
| LillyDirect Pharmacy, LLC | SEC 10-K |
| Loxo Oncology, Inc. | SEC 10-K |
| Mablink Bioscience S.A.S. | SEC 10-K |
| Manet Holdings LLC | SEC 10-K |
| Morphic Holding, Inc. | SEC 10-K |
| Morphic Therapeutic UK Ltd. | SEC 10-K |
| Morphic Therapeutic, Inc. | SEC 10-K |
| NexPharm Parent Holdco, LLC | SEC 10-K |
| OY Eli Lilly Finland AB | SEC 10-K |
| Pandinus MSC, Inc. | SEC 10-K |
| Petra Pharma Corporation | SEC 10-K |
| Pharmaserve-Lilly S.A.C.I. | SEC 10-K |
| Point Biopharma Corp. | SEC 10-K |
| Point Biopharma Global Inc. | SEC 10-K |
| Point Biopharma USA Inc. | SEC 10-K |
| Prevail Therapeutics Inc. | SEC 10-K |
| Protomer Technologies, Inc. | SEC 10-K |
| SGX Pharmaceuticals, Inc. | SEC 10-K |
| Scorpion Therapeutics, Inc. | SEC 10-K |
| Sigilon Therapeutics Inc. | SEC 10-K |
| SiteOne Therapeutics, Inc. | SEC 10-K |
| Spaly Bioquimica, S.A. | SEC 10-K |
| UAB Eli Lilly Lietuva | SEC 10-K |
| Valquifarma, S.A. | SEC 10-K |
| Versanis Bio Australia PTY LTD | SEC 10-K |
| Versanis Bio, Inc. | SEC 10-K |
| Verve Therapeutics, Inc. | SEC 10-K |
| Victoria Holdco Corp. | SEC 10-K |
| Vitalfarma - Produtos Farmaceuticos, Lda. | SEC 10-K |
Recent filings
94 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
146 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Eli Lilly & Co in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
| Universe Pharmaceuticals IncUPC | Ji'An, Jiangxi, China | $17.86B | -$3.67B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Eli Lilly & Co's CIK number?
- Eli Lilly & Co's SEC Central Index Key (CIK) is 59478.
- What is Eli Lilly & Co's stock ticker?
- Eli Lilly & Co trades as NYSE: LLY.
- What was Eli Lilly & Co's revenue?
- Eli Lilly & Co reported revenue of $65.18B for the fiscal year ended Dec 31, 2025, +44.7% from the year before.
- When does Eli Lilly & Co's fiscal year end?
- Eli Lilly & Co's fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Eli Lilly & Co headquartered?
- Eli Lilly & Co's principal executive office on file with the SEC is in Indianapolis, IN.
- What companies does Eli Lilly & Co own?
- Eli Lilly & Co lists 157 subsidiaries in its SEC filings and other public records, including ARMO Biosciences, Inc., Adverum Biotechnologies, Inc., Adverum NC, LLC.
- Does Eli Lilly & Co sponsor H-1B visas?
- Department of Labor records show 334 certified H-1B filings and 24 certified PERM filings under the name Eli Lilly & Co.
- Has Eli Lilly & Co had any FDA recalls?
- The FDA lists 5 recalls with Eli Lilly & Co as the recalling firm. The latest started Mar 12, 2024.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026